General
Will the US FDA approve an 'in vivo' gene-editing therapy for a non-fatal chronic disease before the end of 2028?
A science prediction on a major breakthrough in genetic medicine, moving from editing cells outside the body to inside the body (in vivo).
81 total votes
Analysis
In Vivo Gene Editing: FDA Approval by 2028?
The first CRISPR-based therapies approved (like Exa-cel for sickle cell disease) are 'ex vivo' (cells edited outside the body). This prediction asks if the FDA will approve an **'in vivo'** therapy (delivered and edited directly inside the body) for a non-fatal, chronic disease (e.g., severe high cholesterol or specific blindness forms) before the end of 2028.
Delivery Breakthroughs
The majority 'Yes' vote is due to scientific momentum. Clinical trials for *in vivo* therapies using lipid nanoparticles (LNP) for liver-based editing are showing promising safety and efficacy. Researchers believe the long-term data required for chronic diseases will be strong enough to secure FDA approval for the first non-fatal, systemic gene-editing drug within the next three years, opening the door to treating hundreds of genetic conditions.